CDH9

Across TCGA pan-cancer cohorts, CDH9 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated CDH9 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CDH9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDH9 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCS show a favorable association.

ACC, CESC, and BRCA are the cancer types where CDH9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.256	0.809	<.001	36	view →
CESC	OS	Median	All	0.094	0.587	.015	12	view →
BRCA	OS	Median	All	0.141	0.579	.016	12	view →
BLCA	OS	Median	III,IV	0.141	0.581	.011	6	view →
SCLC	OS	Median	III,IV	0.164	0.670	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	IV	0.322	0.725	.034	6	view →
SKCM	OS	Median	All	0.935	0.860	.018	6	view →
READ	OS	Median	III,IV	0.644	0.932	<.001	5	view →
UCS	DFS	Median	II,III,IV	1.000	0.244	.033	4	view →
UCEC	DFS	Median	All	0.771	0.627	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

CDH9–ACC (OS)

Open the ACC breakdown →